Theratechnologies Board of Directors Appoints Former Merck Canada President

Theratechnologies Board of Directors Appoints Former Merck Canada President 
MONTREAL, CANADA -- (Marketwired) -- 04/09/13 -- Mr. Paul Pommier,
Chair of the Board of Directors of Theratechnologies Inc.
(Theratechnologies) (TSX:TH), today announced the appointment of Mrs.
Dawn Graham as a member of its Board.  
Until recently, Dawn Graham was president of the Europe/Canada region
for Merck & Co., a multinational pharmaceutical corporation. This
position represented the culmination of a 23 year career with this
corporation. She had previously served as president of Merck Canada.
At that time, she was returning from a two year stay abroad where she
held the positions of Vice President, Asia Pacific, and, prior to
this, Vice President, Global Marketing for the Arthritis, Analgesics
and Osteoporosis franchise. She had previously particularly
distinguished herself at Merck Canada as Vice President, Sales, and
Vice President, Corporate Affairs. 
Board members and its current Chair, Paul Pommier, intend, if they
are re-elected during the next annual meeting of shareholders to be
held on May 24, to appoint Mrs. Graham as Chair of the Board of
Directors at the meeting of the Board that will be held immediately
after the annual meeting. 
"Dawn has a strong and vast experience of the Canadian and
international pharmaceutical sectors. Her knowledge represents an
important asset for Theratechnologies' Board which will undoubtedly
benefit from her strategic vision as we pursue our goal to create
greater value for tesamorelin," said Paul Pommier, Chair of
Theratechnologies' Board of Directors. 
"I am proud to be joining the ranks of Theratechnologies. As I am
very familiar with the issues that biopharmaceutical companies are
facing, I intend to support the Board by building on the experience I
have acquired in the industry over the last thirty years and thus
promote Theratechnologies' development," added Dawn Graham, member of
Theratechnologies' Board of Directors. 
Over and above the positions she held at Merck, Mrs. Graham also
served as Chair of the Board of Directors of Rx&D, the national
association representing research-based pharmaceutical companies in
Canada, as well as Chair of the Board of the Merck/Schering-Plough
joint venture. She has also been an active member on many
 boards of
directors. 
A Montreal-native, Mrs. Graham is bilingual. 
About Theratechnologies  
Theratechnologies (TSX:TH) is a biopharmaceutical company that
specializes in innovative therapeutic peptide products, with an
emphasis on growth-hormone releasing factor peptides. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on the
Securities and Exchange Commission's website at www.sec.gov. 
Contacts:
Denis Boucher
NATIONAL Public Relations
514 843-2393